Brought to you by 
Abbott buys Biocompatibles' stent business
11 Sep 2020
Executive Summary
Abbott Laboratories is buying UK medical device company Biocompatibles' cardiovascular stent business for $234.5mm in cash. The deal gives Abbott worldwide manufacturing, marketing, development, and distribution rights to the BiodivYsio cardiovascular stent line it has been selling exclusively in the US since 1999, when it licensed the rights from Biocompatibles.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott buys Biocompatibles' stent business
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice